ANVS
Annovis Bio, Inc.
$1.79
-5.29%
$61.3M
No data for this timeframe.
Vol
Market Cap$61.3M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders5 funds
Inst. Value$5.2M
Inst. Activity5 buys / 0 sells
Insider Activity2B / 0S
Insider Net $$1.5M
Reddit Sentiment57° Neutral
SEC Reports5
Press Releases2
Recent Activity
Jun 5, 2026
short_volume
Short Volume: ANVS — 56.7% short (0.4M / 0.8M)
Short: 441,334 | Exempt: 3,800 | TRF Vol: 777,887 | Short Ratio: 56.7% | Off-exchange volume (dark p
May 20, 2026
SEC
Annovis Bio is raising approximately $13.8M in net proceeds through a dilutive offering of 7.9M shares and warrants, pri
424B5 — Impact 6/10
May 20, 2026
Insider
Hoffman Michael B bought 2,562 shares
Director @ $1.75 ($4.5K)
May 19, 2026
SEC
Annovis Bio filed a preliminary 424B5 for an underwritten offering of common stock and warrants, with no final pricing d
424B5 — Impact 7/10
May 15, 2026
SEC
Annovis Bio reported Q1 2026 results showing increased net loss per share ($0.63 vs $0.32) and cash burn, but highlighte
8-K — Impact 5/10
Apr 2, 2026
Insider
Hoffman Michael B bought 713,800 shares
Director @ $2.10 ($1.5M)
Inst.
VANGUARD GROUP INC — ADD
923,201 shares ($3.2M)
Inst.
TWO SIGMA INVESTMENTS, LP — NEW
551,837 shares ($1.9M)
Price Targets
$12.50
+606.2% upside
Strong Buy
Current $1.77
Low $8.00
Median $12.50
High $17.00
2 analysts
$8.00
$17.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 14, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.48 ▼ -65.5% | $-0.48 — $-0.48 | -50% YoY | 1 |
| Next Q | $-0.44 ▼ -57.1% | $-0.44 — $-0.44 | -19% YoY | 1 |
| Current FY | $-1.80 ▼ -57.9% | $-1.80 — $-1.80 | -29% YoY | 1 |
| Next FY | $-1.16 ▲ +14.7% | $-1.16 — $-1.16 | 36% YoY | 1 |
Latest Reports
BEARISH
424B5
6/10
Annovis Bio is raising approximately $13.8M in net proceeds through a dilutive offering of 7.9M shares and warrants, pri
May 20, 2026
BEARISH
424B5
7/10
Annovis Bio filed a preliminary 424B5 for an underwritten offering of common stock and warrants, with no final pricing d
May 19, 2026
NEUTRAL
Press
4/10
Annovis Bio has partnered with NeuroRPM to integrate an FDA-cleared AI-powered digital biomarker platform into its ongoi
Mar 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $3.2M | ADD |
| TWO SIGMA INVESTMENTS, LP | $1.9M | NEW |
| WELLS FARGO & COMPANY/MN | $49.5K | ADD |
| MORGAN STANLEY | $34.3K | ADD |
| BANK OF AMERICA CORP | $716.00 | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 20, 2026 | Hoffman Michael | BUY | $4.5K |
| Apr 2, 2026 | Hoffman Michael | BUY | $1.5M |
Reddit Sentiment
57°
Neutral
Bearish
Neutral
Bullish
5 institutional holders with $5.2M total value (1,499,453 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, WELLS. Net buying activity: 5 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 923,201 | $3.2M | 61.6% | ADD +25.1% |
| 2 | TWO SIGMA INVESTMENTS, LP | 551,837 | $1.9M | 36.8% | NEW |
| 3 | WELLS FARGO & COMPANY/MN | 14,307 | $49.5K | 1.0% | ADD +46.8% |
| 4 | MORGAN STANLEY | 9,901 | $34.3K | 0.7% | ADD +34.0% |
| 5 | BANK OF AMERICA CORP /DE/ | 207 | $716.00 | 0.0% | ADD +42.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 738,003 | 923,201 | +25.1% | $3.2M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 551,837 | — | $1.9M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 9,746 | 14,307 | +46.8% | $49.5K | 2025-Q4 |
| MORGAN STANLEY | ADD | 7,389 | 9,901 | +34.0% | $34.3K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 145 | 207 | +42.8% | $716.00 | 2025-Q4 |
| MORGAN STANLEY | TRIM | 12,194 | 7,389 | -39.4% | $15.3K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 26,317 | 633 | -97.6% | $1.3K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 160,876 | 26,317 | -83.6% | $57.1K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 166,219 | 0 | -100.0% | $0.00 | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 21,800 | 0 | -100.0% | $0.00 | 2025-Q2 |
| VANGUARD GROUP INC | ADD | 466,277 | 647,920 | +39.0% | $971.9K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 10,923 | 166,219 | +1421.7% | $249.3K | 2025-Q1 |
| UBS Group AG | DOUBLED | 48,736 | 160,876 | +230.1% | $241.3K | 2025-Q1 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 535,707 | 125,300 | -76.6% | $187.9K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 21,800 | — | $32.7K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 1,300 | 10,189 | +683.8% | $15.3K | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 385,092 | 535,707 | +39.1% | $2.7M | 2024-Q4 |
| UBS Group AG | DOUBLED | 1,847 | 48,736 | +2538.7% | $245.1K | 2024-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 5,498 | 1,350 | -75.4% | $10.9K | 2024-Q3 |
1 unique insiders with 2 transactions. Net insider value: $1.5M ($1.5M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 20, 2026 | Hoffman Michael B | Director | BUY | 2,562 | $1.75 | $4.5K |
| Apr 2, 2026 | Hoffman Michael B | Director | BUY | 713,800 | $2.10 | $1.5M |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 2 mixed, 0 neutral. Avg impact: 6.0/10.
BEARISH
424B5
6/10
Annovis Bio is raising approximately $13.8M in net proceeds through a dilutive offering of 7.9M shar
May 20, 2026
BEARISH
424B5
7/10
Annovis Bio filed a preliminary 424B5 for an underwritten offering of common stock and warrants, wit
May 19, 2026
MIXED
8-K
5/10
Annovis Bio reported Q1 2026 results showing increased net loss per share ($0.63 vs $0.32) and cash
May 15, 2026
BEARISH
PRESS-RELEASE
6/10
Annovis Bio reported Q1 2026 EPS of -$0.63, significantly below the -$0.35 consensus estimate, with
May 15, 2026
MIXED
PRESS-RELEASE
6/10
Annovis Bio reported a wider-than-expected EPS loss of $-0.39 (vs $-0.36 est) with no revenue, but s
Apr 10, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$12.50 mean target
+606.2% upside
Strong Buy (1.50)
$8.00 Low
$17.00 High
| Metric | Value |
|---|---|
| Current Price | $1.77 |
| Target Low | $8.00 |
| Target Mean | $12.50 |
| Target Median | $12.50 |
| Target High | $17.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.48 | $-0.48 | $-0.48 | -50.0% | -65.5% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.44 | $-0.44 | $-0.44 | -18.9% | -57.1% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-1.80 | $-1.80 | $-1.80 | -28.6% | -57.9% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-1.16 | $-1.16 | $-1.16 | 35.6% | +14.7% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.480 | |
| 7d ago | $-0.290 | -0.190 |
| 30d ago | $-0.290 | -0.190 |
| 60d ago | $-0.310 | -0.170 |
| 90d ago | $-0.280 | -0.200 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 14, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
57°
Neutral
Bearish
Neutral
Bullish
3 mentions
1 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 6, 2026 | 2 | 58° Warm | 1 | 0 | 2 |
| May 6, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jun 5, 2026
short_volume
Short Volume: ANVS — 56.7% short (0.4M / 0.8M)
Short: 441,334 | Exempt: 3,800 | TRF Vol: 777,887 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
short_volume
Short Volume: ANVS — 66.4% short (0.7M / 1.1M)
Short: 737,392 | Exempt: 4,485 | TRF Vol: 1,111,145 | Short Ratio: 66.4% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: ANVS — 69.0% short (0.5M / 0.8M)
Short: 524,007 | Exempt: 915 | TRF Vol: 759,795 | Short Ratio: 69.0% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: ANVS — 55.4% short (0.3M / 0.6M)
Short: 306,113 | Exempt: 1,112 | TRF Vol: 552,484 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
May 19, 2026
offering
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
<p>MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnolog
May 15, 2026
earnings
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
<p>MALVERN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnolog
May 13, 2026
earnings_calendar
ANVS Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings_calendar
ANVS Q1 2026 Earnings Scheduled — 2026-05-11
Apr 23, 2026
short_volume
Short Volume: ANVS — 65.4% short (0.4M / 0.6M)
Short: 422,868 | Exempt: 440 | TRF Vol: 646,953 | Short Ratio: 65.4% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
short_volume
Short Volume: ANVS — 63.9% short (0.4M / 0.6M)
Short: 413,916 | Exempt: 1,150 | TRF Vol: 647,769 | Short Ratio: 63.9% | Off-exchange volume (dark pool + OTC)
Apr 17, 2026
short_volume
Short Volume: ANVS — 61.5% short (0.4M / 0.7M)
Short: 445,994 | Exempt: 8,623 | TRF Vol: 725,097 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
short_volume
Short Volume: ANVS — 71.1% short (0.4M / 0.6M)
Short: 424,807 | Exempt: 657 | TRF Vol: 597,647 | Short Ratio: 71.1% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
short_volume
Short Volume: ANVS — 68.8% short (0.6M / 0.8M)
Short: 579,065 | Exempt: 9,591 | TRF Vol: 841,460 | Short Ratio: 68.8% | Off-exchange volume (dark pool + OTC)
Apr 13, 2026
short_volume
Short Volume: ANVS — 75.1% short (1.0M / 1.4M)
Short: 1,027,608 | Exempt: 4,159 | TRF Vol: 1,367,811 | Short Ratio: 75.1% | Off-exchange volume (dark pool + OTC)
Apr 10, 2026
earnings
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
<p>MALVERN, Pa., April 10, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnol